Summary
This Phase 1 project will enable Scandinavian ChemoTech AB (ChemoTech) to develop a business plan for Dynamic-ElectroEnhanced Pain Control (D-EEPC). This will include clinical and market feasibility, with a strong business development and commercialisation strategy.
Approximately 25% of all cancer patients are affected by secondary bone cancer; which is difficult to find and treat. 20-30% of these patients do not respond to current systemic therapies and pain control with narcotic analgesics, radiation therapy and surgery. This patient population continues to experience potentially debilitating back pain.
To address this, ChemoTech has developed D-EEPC - a game-changing pain reduction treatment for secondary bone cancer. It operates by sending short, high voltage electric pulses in combination with a low concentration of a cytostatic drug to reduce tumour size in the spine or bones. This reduces pain caused by pressure on nerves. The different voltage settings and use of an applicator with different sizes allows treatment of hard-to-treat cancers and distinguishes D-EEPC from its competitors.
Development of D-EEPC and research supporting its efficacy and safety to date is extremely promising but requires full clinical validation and an optimal business strategy. The proposed Phase 1 project will enable the company to define the pathway to implement for successful commercialisation.
Approximately 25% of all cancer patients are affected by secondary bone cancer; which is difficult to find and treat. 20-30% of these patients do not respond to current systemic therapies and pain control with narcotic analgesics, radiation therapy and surgery. This patient population continues to experience potentially debilitating back pain.
To address this, ChemoTech has developed D-EEPC - a game-changing pain reduction treatment for secondary bone cancer. It operates by sending short, high voltage electric pulses in combination with a low concentration of a cytostatic drug to reduce tumour size in the spine or bones. This reduces pain caused by pressure on nerves. The different voltage settings and use of an applicator with different sizes allows treatment of hard-to-treat cancers and distinguishes D-EEPC from its competitors.
Development of D-EEPC and research supporting its efficacy and safety to date is extremely promising but requires full clinical validation and an optimal business strategy. The proposed Phase 1 project will enable the company to define the pathway to implement for successful commercialisation.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/866986 |
| Start date: | 01-07-2019 |
| End date: | 31-12-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
This Phase 1 project will enable Scandinavian ChemoTech AB (ChemoTech) to develop a business plan for Dynamic-ElectroEnhanced Pain Control (D-EEPC). This will include clinical and market feasibility, with a strong business development and commercialisation strategy.Approximately 25% of all cancer patients are affected by secondary bone cancer; which is difficult to find and treat. 20-30% of these patients do not respond to current systemic therapies and pain control with narcotic analgesics, radiation therapy and surgery. This patient population continues to experience potentially debilitating back pain.
To address this, ChemoTech has developed D-EEPC - a game-changing pain reduction treatment for secondary bone cancer. It operates by sending short, high voltage electric pulses in combination with a low concentration of a cytostatic drug to reduce tumour size in the spine or bones. This reduces pain caused by pressure on nerves. The different voltage settings and use of an applicator with different sizes allows treatment of hard-to-treat cancers and distinguishes D-EEPC from its competitors.
Development of D-EEPC and research supporting its efficacy and safety to date is extremely promising but requires full clinical validation and an optimal business strategy. The proposed Phase 1 project will enable the company to define the pathway to implement for successful commercialisation.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
EU-Programme-Call
